scholarly journals In silico directed evolution in antibody engineering: a promising approach to improvement antitumor biopharmaceuticals

Author(s):  
Thiago Chaves ◽  
Beatriz Chaves ◽  
Fernando Conte ◽  
Rodrigo Silva ◽  
Patrícia Neves
Author(s):  
Didac Martí ◽  
Eduard Martín-Martínez ◽  
Juan Torras ◽  
Oscar Bertran ◽  
Pau Turon ◽  
...  

Author(s):  
Beat Anton Amrein ◽  
Ashish Runthala ◽  
Shina Caroline Lynn Kamerlin
Keyword(s):  

2009 ◽  
Vol 257 (1) ◽  
pp. 131-141 ◽  
Author(s):  
David C. Wedge ◽  
William Rowe ◽  
Douglas B. Kell ◽  
Joshua Knowles

2011 ◽  
Vol 407 (3) ◽  
pp. 391-412 ◽  
Author(s):  
Olga Khersonsky ◽  
Daniela Röthlisberger ◽  
Andrew M. Wollacott ◽  
Paul Murphy ◽  
Orly Dym ◽  
...  

IUCrJ ◽  
2017 ◽  
Vol 4 (1) ◽  
pp. 50-64 ◽  
Author(s):  
Beat Anton Amrein ◽  
Fabian Steffen-Munsberg ◽  
Ireneusz Szeler ◽  
Miha Purg ◽  
Yashraj Kulkarni ◽  
...  

The tremendous interest in enzymes as biocatalysts has led to extensive work in enzyme engineering, as well as associated methodology development. Here, a new framework for computer-aided directed evolution of enzymes (CADEE) is presented which allows a drastic reduction in the time necessary to prepare and analyzein silicosemi-automated directed evolution of enzymes. A pedagogical example of the application ofCADEEto a real biological system is also presented in order to illustrate theCADEEworkflow.


2021 ◽  
Author(s):  
Samvedna Saini ◽  
Manusmriti Agarwal ◽  
Amartya Pradhan ◽  
Savitha Pareek ◽  
Ashish K Singh ◽  
...  

Abstract Introduction: Computational antibody engineering, affinity maturation, and screening greatly aid in vaccine and therapeutic antibody development by increasing the speed and accuracy of predictions. This study presents a protocol for designing affinity enhancing mutants of antibodies through in silico mutagenesis. A SARS-CoV-2 cross-reactive neutralizing antibody, CR3022, is considered as a case study.Methods: Our study aimed at generating antibody candidates from the human antibody CR3022 (derived from convalescent SARS patient) against the RBD of SARS-CoV-2 via in silico affinity maturation using site-directed mutagenesis in mutation hotspots. We optimized the paratope of the CR3022 antibody towards the RBD of SARS-CoV-2 for better binding affinity and stability, employing molecular modeling, docking, dynamics simulations, and molecular mechanics energies combined with generalized Born and surface area (MM-GBSA). Results: Nine antibody candidates were generated post in silico site-directed mutagenesis followed by preliminary screening. Molecular dynamics simulation of 100 nanoseconds and MM-GBSA analysis confirmed L-K45S as a lead antibody with the highest binding affinity against the RBD compared to wild-type and mutant counterparts. Three out of the remaining mutants were also found to have distinct epitopes and binding, possessing a potential to be developed against emerging SARS-CoV-2 variants of concern. Conclusion: The study demonstrates the use of an integrative antibody engineering protocol for enhancing affinity and neutralization potential through mutagenesis using robust open-source computational tools and predictors. This study highlights unique scoring and ranking methods for evaluating docking efficiency. It also underscores the importance of framework mutations for developing broadly neutralizing antibodies.


2021 ◽  
Author(s):  
Saleh Riahi ◽  
Jae Hyeon Lee ◽  
Shuai Wei ◽  
Robert Cost ◽  
Alessandro Masiero ◽  
...  

Abstract As the COVID-19 pandemic continues to spread, hundreds of new initiatives including studies on existing medicines are running to fight the disease. To deliver a potentially immediate and lasting treatment to current and emerging SARS-CoV-2 variants, new collaborations and ways of sharing are required to create as many paths forward as possible. Here we leverage our expertise in computational antibody engineering to rationally design/engineer three previously reported SARS-CoV neutralizing antibodies and share our proposal towards anti-SARS-CoV-2 biologics therapeutics. SARS-CoV neutralizing antibodies, m396, 80R, and CR-3022 were chosen as templates due to their diversified epitopes and confirmed neutralization potency against SARS-CoV (but not SARS-CoV-2 except for CR3022). Structures of variable fragment (Fv) in complex with receptor binding domain (RBD) from SARS-CoV or SARS-CoV-2 were subjected to our established in silico antibody engineering platform to improve their binding affinity to SARS-CoV-2 and developability profiles. The selected top mutations were ensembled into a focused library for each antibody for further screening. In addition, we convert the selected binders with different epitopes into the trispecific format, aiming to increase potency and to prevent mutational escape. Lastly, to avoid antibody induced virus activation or enhancement, we suggest application of NNAS and DQ mutations to the Fc region to eliminate effector functions and extend half-life.


2021 ◽  
Author(s):  
Tatsuaki Kurata ◽  
Chayan Kumar Saha ◽  
Jessica A Buttress ◽  
Toomas Mets ◽  
Tetiana Brodiazhenko ◽  
...  

Toxin-Antitoxin (TA) gene pairs are ubiquitous in microbial chromosomal genomes and plasmids, as well as bacteriophages. They act as regulatory switches, with the toxin limiting the growth of bacteria and archaea by compromising diverse essential cellular targets, and the antitoxin counteracting the toxic effect. To uncover previously uncharted TA diversity across microbes and bacteriophages, we analysed the conservation of genomic neighbourhoods using our computational tool FlaGs (for Flanking Genes), which allows high-throughput detection of TA-like operons. Focussing on the widespread but poorly experimentally characterised antitoxin domain DUF4065, our in silico analyses indicated that DUF4065-containing proteins serve as broadly distributed antitoxin components in putative TA-like operons with dozens of different toxic domains with multiple different folds. Given the versatility of DUF4065, we have renamed the domain to Panacea (and proteins containing the domain, PanA) after the Greek goddess of universal remedy. We have experimentally validated nine PanA-neutralised TA pairs. While the majority of validated PanA-neutralised toxins act as translation inhibitors or membrane disruptors, a putative nucleotide cyclase toxin from a Burkholderia prophage compromises replication and translation, as well as inducing RelA-dependent accumulation of the nucleotide alarmone (p)ppGpp. We find that Panacea-containing antitoxins form a complex with their diverse cognate toxins, characteristic of the direct neutralisation mechanisms employed by Type II TA systems. Finally, through directed evolution we have selected PanA variants that can neutralise non-cognate TA toxins, thus experimentally demonstrating the evolutionary plasticity of this hyperpromiscuous antitoxin domain.


Sign in / Sign up

Export Citation Format

Share Document